Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness

Annals of Clinical Psychiatry

Volumn 19, Issue 3, 2007, Pages 153-159

  Fava, Maurizio ^a   Thase, Michael E ^b   Debattista, Charles ^c   Doghramji, Karl ^d   Arora, Sanjay ^e   Hughes, Rod J ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e CEPHALON INC   (United States)

Author keywords

Augmentation; Fatigue; Major depressive disorder; Modafinil; SSRI therapy; Wakefulness

Indexed keywords

MODAFINIL; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EPWORTH SLEEPINESS SCALE; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; NAUSEA; NERVOUSNESS; PAIN; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; WAKEFULNESS; XEROSTOMIA;

ADULT; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLACEBOS; RETROSPECTIVE STUDIES; SLEEP DISORDERS;

EID: 34548309168     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230701464858     Document Type: Article

References (29)

1. Fava M, Davidson KG: Definition and epidemiology of treatment-resistant depression. Psychiatr Clin NA 1996; 19:179-200
2. Nierenberg AA, Keefe BR, Leslie VC, Alport JE, Pava JA, Worthington JJ, Rosenbaum JF, Fava M: Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60:221-225
3. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A: Residual symptoms after partial remission: An important outcome in depression. Psychol Med 1995; 25:1171-1180
4. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rick JA, Keller MB: Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50:97-108
5. Fava M: Management of nonresponse and intolerance: Switching strategies. J Clin Psychiatry 2000; 61 (Suppl 2):10-12
6. Fava M: Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001; 62 (Suppl 18):4-11
7. Nelson JC: Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61 (Suppl 2):13-19
8. Menza MA, Kaufman KR, Castellanos A: Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61:378-381
9. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR: Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64:1057-1064
10. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J: A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 2004; 24:87-90
11. Fava M, Thase ME, DeBattista C: A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66:85-93
12. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
13. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
14. Johns MW: A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 1991; 14:540-545
15. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46:1121-1123
16. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, rev ed. Rockville, Md: US Department of Health and Human Services; 1976
17. Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72:115-127
18. Landen M, Bjorling G, Agren H, Fahlen T: A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59:664-668
19. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH: Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62:448-452
20. Mischoulon D, Fava M, Rosenbaum JF: Strategies for augmentation of SSRI treatment: A survey of an academic psychopharmacology practice. Harv Rev Psychiatry 1999; 6:322-326
21. Baker M, Dorzab J, Winokur G, Cadoret RJ: Depressive disease: Classification and clinical characteristics. Compr Psychiatry 1971; 12:354-365
22. Maurice-Tison S, Verdoux H, Gay B, Perez P, Salamon R, Bourgeois ML: How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract 1998; 48:1245-1246
23. Tylee A, Gastpar M, Lepine JP, Mendlewicz J: DEPRES II (Depression Research in European Society II): A patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999; 14:139-151
24. Beasley CM, Jr., Koke SC, Nilsson ME, Gonzales JS: Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis. Clin Ther 2000; 22:1319-1330
25. Zajecka JM: Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000; 61 (Suppl 2):20-25
26. Schwartz TL, Azhar N, Cole K, Hopkins G, Nihilani N, Simionescu M, Hussain J, Jones N: An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J Clin Psychiatry 2004; 65:1223-1227
27. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43:88-97
28. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000; 54:1166-1175
29. Pack AI, Black JE, Schwartz JR, Matheson JK: Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164:1675-1681